|
1
|
Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved?
|
Nat Rev Microbiol
|
2006
|
3.13
|
|
2
|
Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission.
|
Annu Rev Med
|
2008
|
2.81
|
|
3
|
Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
|
PLoS Med
|
2008
|
2.74
|
|
4
|
Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages.
|
J Virol
|
2011
|
2.55
|
|
5
|
Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study.
|
Anal Chem
|
2008
|
2.12
|
|
6
|
IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis.
|
J Immunol
|
2005
|
2.00
|
|
7
|
In vitro and in vivo: the story of nonoxynol 9.
|
J Acquir Immune Defic Syndr
|
2005
|
1.99
|
|
8
|
The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells.
|
J Virol
|
2005
|
1.54
|
|
9
|
MiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV(162P3) in cynomolgus macaques.
|
PLoS Pathog
|
2012
|
1.07
|
|
10
|
Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates.
|
AIDS Res Hum Retroviruses
|
2006
|
1.06
|
|
11
|
Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines.
|
Antiviral Res
|
2010
|
1.04
|
|
12
|
Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity.
|
J Virol
|
2014
|
0.94
|
|
13
|
In vitro anti-HIV and -HSV activity and safety of sodium rutin sulfate as a microbicide candidate.
|
Antiviral Res
|
2007
|
0.89
|
|
14
|
Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen.
|
Vaccine
|
2010
|
0.88
|
|
15
|
Interleukin-8 levels in seminal plasma in chronic prostatitis/chronic pelvic pain syndrome and nonspecific urethritis.
|
BJU Int
|
2006
|
0.88
|
|
16
|
A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions.
|
Proteins
|
2007
|
0.87
|
|
17
|
DC-SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4.
|
PLoS One
|
2011
|
0.85
|
|
18
|
Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010.
|
J Transl Med
|
2011
|
0.82
|
|
19
|
Microbicides 2006 conference.
|
AIDS Res Ther
|
2006
|
0.80
|
|
20
|
Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.
|
J Acquir Immune Defic Syndr
|
2016
|
0.78
|
|
21
|
Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference.
|
J Transl Med
|
2010
|
0.78
|
|
22
|
Shaping the science of prevention.
|
IAVI Rep
|
2014
|
0.75
|
|
23
|
A plea for justice for jailed medical workers.
|
Science
|
2006
|
0.75
|